Hormonal
GLP-1 receptor agonists (specifically liraglutide and semaglutide) reduce major adverse cardiovascular events (MACE), with benefits potentially driven by anti-atherogenic or plaque-stabilization properties, particularly in secondary prevention.
If you have Type 2 Diabetes and heart disease, injectable GLP-1 medications like liraglutide or semaglutide have been shown to reduce the risk of heart attack, stroke, and cardiovascular death. These benefits appear to come from protecting blood vessels (anti-atherogenic effects). Oral alternatives like DPP-4 inhibitors do not offer this specific heart protection.
Results from CVOTs with GLP-1 RA have been mixed... although trials with liraglutide (75) and semaglutide (74) were positive... If the cardiovascular protection of GLP-1 RAs, in fact, originates from their anti-atherogenic or plaque-stabilization properties... the magnitude of relative cardiovascular benefit from this incretin subclass may be potentially greater in people with early T2D without established cardiovascular disease events
Why this rating
Based on positive trials (LEADER, SUSTAIN-6) but mixed results for other agents (lixisenatide, exenatide).
Source
Glucose Lowering Strategies for Cardiac Benefits: Pathophysiological Mechanisms
Harpreet S. Bajaj et al. · Physiology · 2018
DOI 10.1152/physiol.00004.2018
More from this paper
- SGLT2 inhibitors (specifically empagliflozin and canagliflozin) provide significant cardiovascular benefits, particularly reducing cardiovascular death and heart failure hospitalizations, primarily through hemodynamic mechanisms like intravascular volume reduction, with efficacy potentially modified by the duration of diabetes.Good
- Intensive glycemic control reduces cardiovascular mortality only in patients with early-stage diabetes (duration <10-15 years), whereas it may increase mortality in patients with long-standing diabetes.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →